Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This study is in patients with at least moderate obesity (Body Mass Index [BMI] > 30 kg/m2 or approximately 30 or more pounds overweight) and who also produce too much insulin (insulin stores sugar as fat). Sandostatin LAR® Depot suppresses insulin, and is being developed to help with weight loss in people who find it hard to lose weight on their own because they produce too much insulin.
The main purpose of the study is to find the lowest dose of Sandostatin LAR® Depot that safely helps overweight people lose weight. The study will also compare weight loss in obese patients who receive one of three different dosages of Sandostatin LAR Depot or placebo.
Sex
Ages
Volunteers
Inclusion criteria
You may qualify for this study if you:
- are between the ages of 18-70 (male or female)
- are at least moderately obese (BMI > 30 kg/m2 or approximately 30 or more pounds overweight)
- and pass an oral glucose tolerance test (a 3 hour test to determine if your body produces too much insulin)
Exclusion criteria
You are not qualified for this study if you:
- have diabetes
- have been able to lose weight with diet and exercise alone
- have previously received Sandostatin LAR® Depot
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal